Hemagglutination Inhibition Assay

Antibody titer is inferred from the greatest serum dilution that still prevents visible red-cell clumping. The titer converts an inhibition pattern into a comparative measure of antibody activity. A higher endpoint indicates that inhibition remains detectable at greater dilution, allowing investigators to compare immune responses among samples or assess responses following vaccination.

The critical interaction occurs at viral hemagglutinin, the surface protein responsible for binding red blood cells. When antibodies recognize this protein, they interfere with the binding step, so the cells do not clump visibly. This connects the assay pattern to antibody recognition of a viral component rather than to a general change in the red blood cells.

Comparing inhibition results against different viral antigens can reveal antigenic variation, meaning differences in how well antibodies recognize those antigens. Strong inhibition with one antigen but weaker inhibition with another suggests that antibody recognition is not equivalent across the tested viruses or antigen preparations. The assay therefore supports comparisons of antigenic differences.

A basic workflow begins by combining patient serum with a virus or viral antigen, followed by addition of red blood cells and observation of clumping. The key readout is the inhibition pattern: when antibodies block hemagglutinin-mediated attachment, visible agglutination is prevented. This sequence links antibody binding with a directly observable result.

In clinical and vaccine-related studies, the result can provide evidence of antibody activity associated with prior infection, an immune response, or vaccine-induced protection. Its titer offers an estimate that supports comparisons between samples rather than merely recording whether serum reacts. Interpretation remains connected to the viral antigen tested in the assay.

The assay is used for influenza surveillance, serological diagnosis, and vaccine evaluation. Surveillance studies can compare inhibition patterns produced by circulating viral antigens, while vaccine studies can assess antibody responses against a tested antigen. Because the readout also supports antigenic comparisons, the method links immune measurement with monitoring of viral variation.